# EDGAR Filing Document

**Accession Number:** 0001739174
**File Stem:** 0001213900-26-007701
**Filing Date:** 2026-1
**Character Count:** 18619
**Document Hash:** ac50d8500341186e3309054704566d3c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-007701.hdr.sgml**: 20260126

**ACCESSION NUMBER**: 0001213900-26-007701

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260126

**DATE AS OF CHANGE**: 20260126

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BiomX Inc.
- **CENTRAL INDEX KEY:** 0001739174
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823364020
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90744
- **FILM NUMBER:** 26560529

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 22 EINSTEIN ST.
- **STREET 2:** FLOOR 4
- **CITY:** NESS ZIONA
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972 723942377

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 22 EINSTEIN ST.
- **STREET 2:** FLOOR 4
- **CITY:** NESS ZIONA
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chardan Healthcare Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180430
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Yeganeh Reuven
- **CENTRAL INDEX KEY:** 0002044677

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** HASIRIM 48
- **CITY:** GIRAT SHEMYEL
- **STATE:** L3
- **ZIP:** 00000

## Exhibit 99.5

**Exhibit 99.5**

**<u>JOINT FILING AGREEMENT</u>**

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.0001 per share, of BiomX, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein.

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.

Dated: January 22, 2026

---

| | |
|:---|:---|
| **PYU PYU CAPITAL, LLC** | **PYU PYU CAPITAL, LLC** |
| By: | /s/ Reuven Yeganeh |
| Name: | Reuven Yeganeh |
| Title: | Managing Member |
| **REUVEN YEGANEH** | **REUVEN YEGANEH** |
| /s/ Reuven Yeganeh | /s/ Reuven Yeganeh |
| Name: | Reuven Yeganeh |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**BiomX Inc.**

*(Name of Issuer)*

**Common stock, $0.0001 par value**

*(Title of Class of Securities)*

**09090D301**

*(CUSIP Number)*

**Rick Werner, Esq.**<br>Haynes and Boone, LLP<br>30 Rockefeller Plaza, 26th Floor<br>New York NY 10112<br>(212) 659-7300

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/26/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **09090D301** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pyu Pyu Capital, LLC** | Name of reporting person<br>**Pyu Pyu Capital, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**381422.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**381422.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**381422.00** | Aggregate amount beneficially owned by each reporting person<br>**381422.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) Includes (i) 1,650,000 shares of Common stock, $0.0001 par value ("Common Stock") of BiomX Inc. (the "Issuer") issuable upon the conversion of shares of Series Y Convertible Preferred Stock, par value $0.0001 per share ("Series Y Preferred Stock"), of the Issuer (subject to a 19.99% beneficial ownership limitation), and (ii) 3,300,000 shares of Common Stock of the Issuer issuable upon exercise of warrants (subject to a 19.99% beneficial ownership limitation), as further disclosed in Item 3 of this Schedule 13D.

(2) The figure in Item 13 is based upon (i)  1,526,640 shares of Common Stock of the Issuer outstanding as of November 11, 2025 (as adjusted for the Company's 1:19  reverse stock split which became effective on November 25, 2025 (the "Reverse Stock Split")) , as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed by the Issuer with the SEC on November 12, 2025, (ii) 1,650,000 shares of Common Stock issuable upon the conversion of shares of Series Y Preferred Stock (subject to a 19.99% beneficial ownership limitation), and (ii) 3,300,000 shares of Common Stock of the Issuer issuable upon exercise of warrants (subject to a 19.99% beneficial ownership limitation), as further disclosed in Item 3 of this Schedule 13D.

| **CUSIP No.** | **09090D301** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Reuven Yeganeh** | Name of reporting person<br>**Reuven Yeganeh** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**L3** | Citizenship or place of organization<br>**L3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**381422.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**381422.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**381422.00** | Aggregate amount beneficially owned by each reporting person<br>**381422.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) Includes (i) 1,650,000 shares of Common stock, $0.0001 par value ("Common Stock") of BiomX Inc. (the "Issuer") issuable upon the conversion of shares of Series Y Convertible Preferred Stock, par value $0.0001 per share ("Series Y Preferred Stock"), of the Issuer (subject to a 19.99% beneficial ownership limitation), and (ii) 3,300,000 shares of Common Stock of the Issuer issuable upon exercise of warrants (subject to a 19.99% beneficial ownership limitation), as further disclosed in Item 3 of this Schedule 13D.

(2) The figure in Item 13 is based upon (i) 1,526,640 shares of Common Stock of the Issuer outstanding as of November 11, 2025 (as adjusted for the Company's 1:19  Reverse Stock Split), as disclosed in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed by the Issuer with the SEC on November 12, 2025, (ii) 1,650,000 shares of Common Stock issuable upon the conversion of shares of Series Y Preferred Stock (subject to a 19.99% beneficial ownership limitation), and (ii) 3,300,000 shares of Common Stock of the Issuer issuable upon exercise of warrants (subject to a 19.99% beneficial ownership limitation), as further disclosed in Item 3 of this Schedule 13D.

(3) Mr. Yeganeh is the Managing Member of Pyu Pyu Capital, LLC and shares voting and investment power over shares held by such entity and disclaims beneficial ownership over any securities in which he does not have any pecuniary interest.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common stock, $0.0001 par value

**(b) Name of Issuer:**
BiomX Inc.

**(c) Address of Issuer's Principal Executive Offices:**
22 Einstein St., Floor 4, Ness Ziona, L3, 7414003

The class of equity securities to which this Schedule 13D relates is the Common Stock, par value $0.0001 per share, of BiomX Inc. The principal executive office of the Issuer is 22 Einstein St., Floor 4, Ness Ziona, Israel 7414003.

**Item 4. Purpose of Transaction**

The Pyu Pyu acquired the securities described in this Schedule 13D pursuant to various transactions and agreements with the Issuer, including without limitation those discussed in Item 3 of this Schedule 13D, which are incorporated herein by reference.

The Reporting Persons intend to review its investment in the Issuer on a continuing basis taking into consideration various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for shares of Common Stock of the Issuer, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of shares of Common Stock of the Issuer or disposal of some or all of the shares of Common Stock of the Issuer owned by the Reporting Persons or otherwise acquired by the Reporting Persons, either in the open market or in privately negotiated transactions.

Any open market or privately negotiated purchases or sales, acquisition recommendations or proposals or other transactions concerning the Issuer may be made at any time without prior notice. Any alternative may depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities, the financial condition, results of operations and prospects of the Issuer and general industry conditions, the availability, form and terms of financing, other investment and business opportunities, general stock market and economic conditions, tax considerations and other factors. Although the foregoing reflects plans and proposals presently contemplated by each Reporting Person with respect to the Issuer, the foregoing is subject to change at any time and dependent upon contingencies and assumed and speculative conditions, and there can be no assurance that any of the actions set forth above will be taken.

Depending upon each factor discussed above and any other factor (which may be unknown at this time) that is, or may become relevant, each Reporting Person may consider, among other things: (a) the acquisition by such Reporting Person of additional securities of the Issuer, the disposition of securities of the Issuer, or the exercise of convertible securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) changes in the present board of directors or management of the Issuer; (e) a material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer's business or corporate structure; (g) changes in the Issuer's articles of incorporation, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing any class of the Issuer's securities to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to those enumerated above.

Except to the extent that the foregoing may be deemed to be a plan or proposal, each Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions specified in clause (a) through (j) of this Item 4 of Schedule 13D. Depending upon the foregoing factors and to the extent deemed advisable in light of their general investment policies, or other factors, each Reporting Person may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer or the shares of Common Stock of the Issuer, or any other actions that could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) through (j) of this Item 4 of Schedule 13D. The foregoing is subject to change at any time, and there can be no assurance that the Reporting Persons will take any of the actions set forth above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The aggregate number and percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Persons is stated in Items 11 and 13 on the cover pages hereto.

**(b)**
Number of shares as to which each Reporting Person has:

(i) sole power to vote or to direct the vote:

See Item 7 on the cover pages hereto.

(ii) shared power to vote or to direct the vote:

See Item 8 on the cover pages hereto.

(iii) sole power to dispose or to direct the disposition of:

See Item 9 on the cover pages hereto.

(iv) shared power to dispose or to direct the disposition of:

See Item 10 on the cover pages hereto.

**(c)**
Except as otherwise described herein, including the acquisitions of shares of Common Stock of the Issuer as disclosed in Item 3 of this Schedule 13D, no transactions in the shares of Common Stock of the Issuer were effected during the past sixty days by any of the Reporting Persons.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 3 and Item 4 of this Schedule 13D are incorporated herein by reference.

Registration Rights Agreement

On December 26, 2025, in connection with the Securities Purchase Agreement, the Issuer entered into a Registration Rights Agreement with Pyu Pyu. Pursuant to the Registration Rights Agreement, the Issuer is required to prepare and file a resale registration statement (the "Registration Statement") with respect to (i) the shares of Common Stock of the Issuer issuable upon conversion of the Series Y Preferred Stock of the Issuer, (ii) the shares of Common Stock of the Issuer issuable upon exercise of the Warrants, and (iii) any shares of Common Stock of the Issuer issuable in connection with any anti-dilution provisions contained in the Certificate of Designation and Warrants.

The Registration Rights Agreement requires the Issuer to file the Registration Statement with the SEC within 30 calendar days following the closing of the transactions contemplated by the Securities Purchase Agreement. The Company agreed to use its commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC within 60 calendar days following the closing of the transactions contemplated by the Securities Purchase Agreement (or within 90 calendar days if the SEC reviews the Registration Statement). The Company is also required to maintain the effectiveness of the Registration Statement for the period specified in the Registration Rights Agreement. The Registration Rights Agreement contains customary covenants and mutual indemnification provisions that are customary for transactions of this type.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, a copy of which is filed as an exhibit to this Schedule 13D and is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pyu Pyu Capital, LLC

**Signature:** /s/ Reuven Yeganeh

**Name/Title:** Reuven Yeganeh/Managing Member

**Date:** 01/26/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Reuven Yeganeh

**Signature:** /s/ Reuven Yeganeh

**Name/Title:** Reuven Yeganeh

**Date:** 01/26/2026